PD-1免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌疗效、短期生存及对细胞免疫功能的影响

邬仁华

doi:10.13406/j.cnki.cyxb.002878

您当前的位置：

首页 >

文章列表页 >

PD-1免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌疗效、短期生存及对细胞免疫功能的影响

基础研究 | 更新时间：2024-01-09

- PD-1免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌疗效、短期生存及对细胞免疫功能的影响
- Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function
- 重庆医科大学学报 2021年46卷第8期页码：882-887
- 作者机构：
  
  成都大学附属医院肿瘤科,成都,610081
- 作者简介：
- 基金信息：
  
  四川省科技厅课题资助项目(2019YJ0652)
- DOI：10.13406/j.cnki.cyxb.002878
  中图分类号： R730.51
- 纸质出版日期：2021，
扫描看全文
邬仁华. PD-1免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌疗效、短期生存及对细胞免疫功能的影响[J]. 重庆医科大学学报, 2021,46(8):882-887.

Wu Renhua. Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function[J]. Journal of Chongqing Medical University, 2021,46(8):882-887.
邬仁华. PD-1免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌疗效、短期生存及对细胞免疫功能的影响[J]. 重庆医科大学学报, 2021,46(8):882-887. DOI： 10.13406/j.cnki.cyxb.002878.

Wu Renhua. Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function[J]. Journal of Chongqing Medical University, 2021,46(8):882-887. DOI： 10.13406/j.cnki.cyxb.002878.

摘要

目的：观察程序性细胞死亡因子1（programmed cell death 1，PD-1）免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌的疗效，并分析其对细胞免疫功能、短期预后和不良反应的影响。方法：选取成都大学附属医院2018年12月至2020年8月收治的Ⅳ期肺腺癌患者67例，按照治疗方式不同分为对照组（n=33）和联合组（n=34），对照组予以化疗+PD-1抑制剂治疗，联合组予以化疗+PD-1抑制剂+贝伐单抗治疗，比较2组患者近期治疗疗效、治疗前后细胞免疫功能、卡氏功能状态（Karnofsky performance status，KPS）评分变化情况、不良反应及无进展生存期。结果：联合组患者治疗总有效率和疾病控制率分别为29.41%和79.41%，显著高于对照组的9.09%和54.55%（P<0.05）；治疗后，联合组患者CD3+、CD4+、CD4+/CD8+显著高于对照组（P<0.05），CD8+与对照组患者比较无统计学差异（P>0.05）；联合组患者KPS评分增加稳定率为73.53%，显著高于对照组患者的45.45%（P<0.05）；联合组患者骨髓抑制、消化道反应、血液毒性、肝肾功能损害及周围神经毒性不良反应发生率与对照组患者比较，差异无统计学意义（P>0.05）；联合组患者中位无进展生存期为9.73个月，对照组患者中位无进展生存期为6.05个月，差异有统计学意义（P<0.05）。结论： PD-1免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌，可明显提高近期治疗疗效，改善患者免疫功能，提高其生存质量，延长其无进展生存时间。

Abstract

Objective: To observe the efficacy of programmed cell death 1 (PD-1) immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma

and to analyze its influence on cellular immune function

short-term prognosis and adverse reactions. Methods: A total of 67 patients with stageⅣlung adenocarcinoma admitted to our hospital between December 2018 and August 2020 were selected in this study and they were divided into control group (n=33) and combined group (n=34) according to different treatment methods. Control group were treated with chemotherapy+PD-1 inhibitor

and combined group were treated with chemotherapy+PD-1 inhibitor+bevacizumab. The short-term treatment efficacy

changes of cellular immune function and Karnofsky performance status (KPS) score before and after treatment

adverse reactions and progression-free survival time were compared between the two groups. Results: The total effective rate of treatment and disease control rate of combined group were 29.41%and 79.41%respectively

which were significantly higher than 9.09%and 54.55%of control group (P<0.05). After treatment

the CD3+

CD4+and CD4+/CD8+in combined group were significantly higher than those in control group (P<0.05)

and there was no significant difference in CD8+compared to control group (P>0.05). The increase and stable rate of KPS score of patients in combined group was significantly higher than that in control group (73.53%vs.45.45%) (P<0.05). There were no significant differences in the incidence of adverse reactions such as bone marrow suppression

gastrointestinal reactions

blood toxicity

liver-kidney functional damage and peripheral neurotoxicity in combined group compared with those in control group (P>0.05). The median progression-free survival time were 9.73 months in combined group and were 6.05 months in control group

with significant differences (P<0.05). Conclusion: PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy of stageⅣlung adenocarcinoma can significantly enhance the short-term treatment efficacy

improve the immune function

promote the quality of life and prolong the progression-free survival time.

关键词

程序性细胞死亡因子1肿瘤微环境免疫治疗抗血管生成非小细胞肺癌免疫功能生存预后

Keywords

programmed cell death 1tumor microenvironmentimmunotherapyanti-angiogenesisnon-small cell lung cancerimmune functionsurvival prognosis

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

免疫治疗在EGFR突变非小细胞肺癌中的研究进展

人自体肝癌细胞裂解物致敏的DC瘤苗对肝癌术后免疫功能的影响

肿瘤相关成纤维细胞在甲状腺癌增殖、侵袭与治疗中的作用

CXCL10/CCL2 信号通路介导肿瘤微环境中宫颈癌的发展

NLR及PLR对晚期尿路上皮癌免疫治疗疗效和预后的预测价值